Hi Chicagoest.

Welcome and thanks for the helpful post. I really found the Lifesciences article quite valuable and re-assuring particularly as it relates to the explanation of the MOA of rvx-208 and thus explaining why they brought some of the Zenith epigenetic platforms back to RVX. This should boost the value of the shares. I guess that as more and more scientists review the MOA and relate this to epigenetic research at the academic level rvx-208 will gain increased credibility within the scientific and pharma communities even as the phase 3 BETonMACE trial proceeds.

However, while the increased scientific understanding of rvx-208 has been, IMHO, incredible I also see that the plans are not commitments with hard deadlines. For example, months ago, February???, during the much welcomed Zenith update, there seemed to be a firm commitment to a NASDAQ IPO. So I inquired recently as to the status of the IPO and I was told that the IPO is a goal but that when and even if it takes place is unknown. This is symptomatic of both Zenith and RVX and Don is the CEO of both!!!

This is why investors are skeptical of putting their money in. A plan needs hard timelines and commitment. This is a serious management issue and shortfall.

I've been invested for a long time and only started paying attention to the blogs and Don's webcasts since January of 2013 and I see a very consistent pattern in Don sort of running of at the mouth and not committing to his statements. I believe he is one of the big reasons for the grossly undervalued share price currently.

Yet, I remain long and hopeful because rvx-208 may well be a blockbuster.

So DYODD and GLTA

Cheers

Toinv